HERANTIS PHARMA

11/26/2026 09:35 am EET

This is a translated version of ”Anti takaa työrauhan tutkimuksen edistämiseen” report, published on 11/26/2026



Antti Siltanen, Analyst
+358 45 119 6869
antti.siltanen@inderes.fi



INDERES CORPORATE CUSTOMER

COMPANY REPORT

Share issue secures runway for research

Herantis secured most of the funding for the Phase II HERMOD trial of HER-096 through a directed share issue. Overall, the size of the offering is broadly in line with our expectations, albeit slightly larger and at a lower subscription price than we had previously modeled. A successful financing round is extremely important for the company, as it eliminates near-term financing risk and allows it to focus on HERMOD, which forms the basis of its value creation. Based on the details of the share issue, we lower our target price to EUR 1.9 (was EUR 2.0), and following the improved financial position and the share price decline, we raise our recommendation to Buy (was Accumulate).

Financing package covers bulk of funding needs until Phase II completion

The size of the offering was in line with the 15–20 MEUR target range announced earlier on Tuesday. In the directed share issue, 12.5 million new shares will be issued at EUR 1.20 per share, a discount of ~14% to Tuesday's closing price. We view the discount as quite moderate, considering Tuesday's closing price (EUR 1.40) and the volume-weighted average price over the last 30 days (VWAP EUR 1.24). The offering will be carried out in two tranches, the second of which (~14.8 MEUR) requires the approval of an Extraordinary General Meeting, which in our view is a formality. In the second tranche, roughly 4.1 million shares (~5.0 MEUR) will be allocated to Joensuun Kauppa ja Kone Oy. Payment for and delivery of these shares are expected to take place only in September 2027.

According to the company, the funds raised will be used for the Phase II clinical trial of HER-096, advancing partnership negotiations, and general corporate purposes. Herantis has previously stated that the direct costs of the trial will be ~20 MEUR and that the company's total funding requirement until the completion of Phase II (H2'29) will be around 30–35 MEUR.

Including the previously secured 8.0 MEUR Horizon Europe grant, the funding raised totals 23 MEUR. Based on current information, the remaining funding requirement for Phase II is thus ~7–12 MEUR. In our view, securing the remaining funding will become relevant in Q4'28–Q1'29, toward the end of the HERMOD trial. We believe the company still has access to a range of financing options, such as partnering, share issues, and research grants.

From a value-creation perspective, the most critical milestone in the coming years is the Phase II readout in 2029. We estimate that the drug could be launched in 2034, provided the trial results support it. We estimate its peak sales potential at ~6 BEUR. The estimate involves significant uncertainty in both directions, as the commercial potential depends on several variables. We estimate the probability of marketing authorization at ~15% based on historical success rates in the industry.

Share issue does not materially change the valuation

We update our model to reflect a slightly higher number of shares and greater proceeds from the share issue than previously estimated. As a result of the changes, the base case of our DCF model indicates a share value of EUR 1.9. We estimate the fair value range of the share to be EUR 0.6–4.8. Our assessment is based on DCF scenarios, where the positive scenario relies on favorable clinical results, non-dilutive research funding, and a rapid timeline. The negative scenario, on the other hand, represents mediocre results, a greater increase in the number of shares than our estimates, and a delay in commercialization.

Recommendation
Buy
(was Accumulate)

Target price:
EUR 1.90
(was EUR 2.00)

Share price:
EUR 1.32

Business risk



Valuation risk




	2025	2026e	2027e	2028e
Revenue	0.0	0.0	0.0	0.0
growth-%	0%	0%	0%	0%
EBIT adj.	-6.4	-5.7	-6.6	-8.6
Net income	-6.6	-5.9	-6.6	-8.6
EPS (adj.)	-0.27	-0.15	-0.17	-0.22
P/E (adj.)	neg.	neg.	neg.	neg.
P/B	neg.	6.0	24.8	neg.
Dividend yield-%	0.0 %	0.0 %	0.0 %	0.0 %
EV/EBIT (adj.)	neg.	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.	neg.
EV/S	>100	>100	>100	>100

Source: Inderes

Guidance

Herantis does not provide any guidance.

Share price



Source: Millistream Market Data AB

Value drivers

- There is a great need for new drugs in Parkinson's disease that affect the progression of the disease.
- If the drug proves safe and effective, we feel that the achievable pricing is attractive.
- In terms of its operating mechanism, HER-096 could also be suitable for treating other neurodegenerative diseases such as Alzheimer's disease and ALS.
- The initial clinical study results are promising for the further development of HER-096.

Risk factors

- The risk of failure in development is very high due to the early development phase.
- The research program is still at an early stage, so Herantis needs substantial financing for drug development.
- A licensing agreement may not be reached or its terms may be unsatisfactory.
- Drugs that may enter the market before HER-096 could raise the threshold for market entry.
- The increase in the number of shares and the dilution of their value through share issues.

Valuation	2026e	2027e	2028e
Share price	1.32	1.32	1.32
Number of shares, millions	39.0	39.0	39.0
Market cap	51	51	51
EV	43	50	58
P/E (adj.)	neg.	neg.	neg.
P/E	neg.	neg.	neg.
P/FCF	12.8	neg.	neg.
P/B	6.0	24.8	neg.
P/S	>100	>100	>100
EV/Sales	>100	>100	>100
EV/EBITDA	neg.	neg.	neg.
EV/EBIT (adj.)	neg.	neg.	neg.
Payout ratio (%)	0.0 %	0.0 %	0.0 %
Dividend yield-%	0.0 %	0.0 %	0.0 %

Source: Inderes

Clinical program moving to Phase II

Drug and mechanism of action

Herantis is a drug development company focused on neurodegenerative diseases. Herantis currently has one candidate in the clinical Phase I, HER-096, which the company develops as a disease-modifying drug for Parkinson's disease. In the future, the drug candidate could also be applicable to other neurodegenerative diseases, such as Alzheimer's disease or ALS.

HER-096 is a *peptidomimetic* administered subcutaneously twice a week. The effects of HER-096 are based on multiple mechanisms: 1) normalization of protein metabolism (proteostasis), 2) reduction of inflammation, 3) prevention of alpha-synuclein accumulation, and 4) normalization of dopamine production. The drug candidate is designed to halt or slow the progression of the disease; no such drug is currently on the market, as existing drugs only alleviate symptoms. The market potential for disease-modifying drugs is significant (read more in our extensive report).

Phase I results support progression of research program

Herantis' Phase I clinical trial showed that HER-096 is well tolerated in short-term use, crosses the blood-brain barrier into the central nervous system, and reaches sufficient concentrations there (see our detailed comment on the results here). We therefore believe that the Phase I results unequivocally support moving on to the Phase II HERMOD trial, which will investigate the tolerability and safety of longer-term dosing, as well as preliminary efficacy. Phase I also identified a suitable dose for further development and the right patient segment.

Phase II trial seeks an efficacy signal

In terms of design, HERMOD is a high-quality randomized, double-blind trial. Its objective is to investigate the tolerability, safety, and preliminary efficacy of HER-096 with longer-term dosing in patients with newly diagnosed Parkinson's disease.

The trial will enroll ~100 patients and last 15 months. The first nine months are double-blind, with half of the participants receiving HER-096 and half receiving a placebo. After that, all participants will receive HER-096, and follow-up will continue for another six months. The duration has been chosen to be long enough for potential differences in symptoms between the treatment and placebo groups to emerge. The first patient is expected to be enrolled in H1'27. An interim readout is planned for H1'29, with full results expected in H2'29.

The trial's primary efficacy endpoint is the Digital Motor Score (DMS), a digital measure of motor function. Herantis conducts the measurements using technology from its partner Indivi. Digital technology can help detect early treatment effects more sensitively than traditional clinical metrics. The trial will also monitor traditional clinical markers of Parkinson's disease, as well as various disease progression biomarkers.

The trial will be conducted at multiple centers in Europe. Herantis has also received positive feedback on the trial design from the US regulator, the FDA. There should therefore be no obstacles to obtaining authorization for a Phase III trial in the US in the future. We estimate that the HERMOD trial will provide valuable additional information on the tolerability and safety profile of HER-096 with longer-term dosing. For drug development to succeed, it is also crucial to obtain a clear and statistically significant efficacy signal to justify a major investment in an expensive Phase III trial, which is decisive for marketing authorization.

Marketing authorization application follows pivotal Phase III trial

If the Phase II results continue to support further development of the candidate, a pivotal Phase 3 study for marketing authorization will still be needed to confirm the candidate's efficacy and safety in larger patient populations with longer-term dosing. The details of this trial will be determined based on the Phase II results. However, it will likely be a multinational, multicenter trial with a significantly larger patient population and a longer duration than the Phase II trial. Its objective will be to demonstrate the efficacy, tolerability, and safety of HER-096 according to the stringent criteria required by regulators.

If the Phase III results are sufficiently strong, a marketing authorization application for HER-096 can be submitted for regulatory review. Besides efficacy and safety, the drug's manufacturing capacity and quality must also meet regulatory requirements. We estimate HER-096’s peak sales potential at ~6 BEUR (detailed calculations in our extensive report and company reports). This estimate is subject to significant uncertainty in both directions, as the commercial potential ultimately depends on many variables, such as the drug’s safety and efficacy, its pricing, and the number of eligible patients. We estimate the probability of marketing authorization at ~15% based on historical success rates in the industry.

Share issue does not materially change the valuation

The valuation is based on risk-adjusted estimates

Herantis is a very high-risk investment because the company's business depends virtually entirely on developing a single drug candidate. In a positive development, Herantis succeeds in commercialization first in Parkinson's disease and later in other neurodegenerative diseases, which could lead to a multi-fold increase in the share price from current levels. On the other hand, poor safety or efficacy results could lead to the loss of the capital invested. Given the historical success rates in drug development, losing the invested capital is a relatively likely outcome. Regarding other indications, the company currently has no clinical program, so our model relies purely on Parkinson's disease at this time.

Our estimate for the probability of HER-096 reaching the market is around 15%. Potentially good results in future studies increase the probability. Our assessment is mainly based on historical probabilities, which we have discussed in this article. Our estimate for post-marketing authorization revenue relies on our assessed patient numbers, the potential sales price of the drug, royalty payments, and other variables, which are described in more detail in our extensive report and the table on the following page.

Valuation is based on DCF model and scenarios

Our valuation is based on risk-weighted estimates that consider the binary risk associated with the probability of success in drug development. In the absence of revenue, our estimate is based on a DCF calculation that models the present value of cash flows far in the future (in the 2030s). Our updated view is based on the latest funding round.

We estimate the valuation through three DCF scenarios, which are presented in the chart below. Based on the scenarios, we determine the fair value of the share to be in a wide range of EUR 0.6-4.8. Note that the scenarios do not represent our view of the best and worst possible paths for the business. Instead, they are intended to give investors a sense of how sensitive the valuation is and of the different paths we consider realistic.

Thus, the DCF model is highly sensitive to the assumptions used. Investors should look at DCF in this type of share more as indicative than a precise indicator of share value. The weighted average cost of capital (WACC) in our DCF model is 12%, which is a typical level for the industry. The recent rise in interest rates puts upward pressure on the WACC, but this is offset by the reduction in the company's financial risk. From a business perspective, WACC is raised by uncertainty of the timing of revenue, the drug's sales price, the achievable revenue, and the terms of possible cooperation agreements, including the royalty percentage. On the other hand, the industry's defensive nature and the strong cash flows resulting from market entry limit the risk level.

A positive option for investors is a scenario in which a larger pharmaceutical company acquires Herantis or licenses the rights to the HER-096 drug candidate on attractive terms. At this stage, we consider the probability of an acquisition relatively low and do not see it as having a significant impact on the expected return. In our opinion, a licensing agreement is a significantly more probable option, which is reflected in the optimistic scenario of our fair value range. The table below shows examples of industry deals from recent years for reference.

DCF valuation ranges

	Optimistic	Pessimistic
Probability of success	30%	10%
Share capital is diluted	0%	50%
Duration of the study program	Based on estimates	Commercialization delay of 1 year
DCF value of the share	4.8	0.6

Source: Inderes

The optimistic scenario assumes a successful Phase 2a study that supports the implementation of the pivotal phase. The study is fully funded on a non-dilutive basis and will be completed in line with our schedule estimate.

The pessimistic scenario is based on clinically uncertain results regarding efficacy and safety, meaning the uncertainty of success remains high. The study program is delayed from the plan, and its financing will increase the number of shares more than we estimate.

Examples of industry agreements 2025–26

Year	Company	Indication	Advance payment	Total value
2025	Arrowhead pharmaceuticals	PD	200	2200
2025	Abl bio	ND	49	2732
2025	Bioarctic	ND	30	802
2026	Scineuro pharmaceuticals	AD	165	1665
2026	Frontier biotechnologies	ND	40	1003
2026	Alzecure pharma	AD	10	1000
2026	Bioarctic	ND	30	800
2026	Alzecure pharma	AD, PD	7	2212

Source: Inderes

PD = Parkinson's disease; AD = Alzheimer's disease; ND = neurodegeneration

Estimates

	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041
HER-096, US												
Prevalence of Parkinson's disease	1,201,025	1,225,045	1,250,000	1,275,000	1,300,000	1,326,000	1,353,000	1,380,000	1,407,000	1,435,000	1,464,000	1,493,000
Eligible patients, %	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%
Potential patients	600,512	612,523	625,000	637,000	650,000	663,000	676,000	690,000	704,000	718,000	732,000	747,000
Market share, %	0%	0%	0%	0%	2%	8%	16%	20%	20%	20%	10%	0%
Patients that stop using the drug, %	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%
Price/year/patient, MEUR	0.02	0.02	0.02	0.02	0.02	0.02	0.03	0.03	0.03	0.03	0.03	0.03
Royalty share, %	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
Revenue	**0**	**0**	**0**	**0**	**34**	**176**	**381**	**496**	**516**	**537**	**286**	**0**
Probability of success	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
Revenue, risk-adjusted	**0**	**0**	**0**	**0**	**5**	**26**	**56**	**72**	**75**	**78**	**42**	**0**
HER-096, other markets												
Prevalence of Parkinson's disease	1,791,078	1,826,900	1,863,000	1,901,000	1,939,000	1,977,000	2,017,000	2,057,000	2,099,000	2,141,000	2,183,000	2,227,000
Eligible patients, %	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%
Potential patients	895,539	913,450	932,000	950,000	969,000	989,000	1,009,000	1,029,000	1,049,000	1,070,000	1,092,000	1,113,000
Market share, %	0%	0%	0%	0%	0%	2%	8%	16%	20%	20%	10%	0%
Patients that stop using the drug, %	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%
Price/year/patient, MEUR	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Royalty share, %	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
Revenue	**0**	**0**	**0**	**0**	**0**	**26**	**137**	**294**	**385**	**400**	**214**	**0**
Probability of success	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
Revenue, risk-adjusted	**0**	**0**	**0**	**0**	**0**	**4**	**20**	**43**	**56**	**58**	**31**	**0**
Top sale, total			**0**	**0**	**226**	**1350**	**3453**	**5266**	**6004**	**6247**	**3333**	**0**
US	0	0	0	0	226	1175	2542	3306	3440	3579	1909	0
Other countries	0	0	0	0	0	175	911	1959	2565	2668	1424	0
Risk-adjusted revenue, total	**0.0**	**0.0**	**0**	**0**	**5**	**30**	**76**	**115**	**131**	**137**	**73**	**0**
US	0.0	0.0	0	0	5	26	56	72	75	78	42	0
Other countries	0.0	0.0	0	0	0	4	20	43	56	58	31	0

Valuation table

Valuation	2021	2022	2023	2024	2025	2026e	2027e	2028e	2029e
Share price	2.40	1.65	1.58	1.52	2.04	**1.32**	**1.32**	**1.32**	**1.32**
Number of shares, millions	11.1	16.9	20.2	20.2	24.1	**39.0**	**39.0**	**39.0**	**39.0**
Market cap	27	28	32	31	49	**51**	**51**	**51**	**51**
EV	26	26	25	29	47	**43**	**50**	**58**	**66**
P/E (adj.)	neg.	neg.	>100	neg.	neg.	**neg.**	**neg.**	**neg.**	**neg.**
P/E	neg.	neg.	>100	neg.	neg.	**neg.**	**neg.**	**neg.**	**neg.**
P/FCF	neg.	neg.	85.9	neg.	96.0	**12.8**	**neg.**	**neg.**	**neg.**
P/B	neg.	neg.	6.8	neg.	neg.	**6.0**	**24.8**	**neg.**	**neg.**
P/S	>100	>100	>100	>100	>100	**>100**	**>100**	**>100**	**>100**
EV/Sales	>100	>100	>100	>100	>100	**>100**	**>100**	**>100**	**>100**
EV/EBITDA	neg.	neg.	>100	neg.	neg.	**neg.**	**neg.**	**neg.**	**neg.**
EV/EBIT (adj.)	neg.	neg.	>100	neg.	neg.	**neg.**	**neg.**	**neg.**	**neg.**
Payout ratio (%)	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	**0.0 %**	**0.0 %**	**0.0 %**	**0.0 %**
Dividend yield-%	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	**0.0 %**	**0.0 %**	**0.0 %**	**0.0 %**

Source: Inderes

The market cap and enterprise value in the table consider the expected change in the number of shares and net debt for the forecast years.

Income statement

Income statement	H1'24	H2'24	2024	H1'25	H2'25	2025	H1'26e	H2'26e	2026e	2027e	2028e	2029e
Revenue	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**
EBITDA	**-2.8**	**-2.3**	**-5.0**	**-3.0**	**-3.4**	**-6.4**	**-3.1**	**-2.6**	**-5.7**	**-6.6**	**-8.6**	**-7.9**
Depreciation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (excl. NRI)	**-2.8**	**-2.3**	**-5.0**	**-3.0**	**-3.4**	**-6.4**	**-3.1**	**-2.6**	**-5.7**	**-6.6**	**-8.6**	**-7.9**
EBIT	**-2.8**	**-2.3**	**-5.0**	**-3.0**	**-3.4**	**-6.4**	**-3.1**	**-2.6**	**-5.7**	**-6.6**	**-8.6**	**-7.9**
Share of profits in assoc. compan.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net financial items	0.0	0.0	0.0	-0.3	0.0	-0.2	-0.2	0.0	-0.2	0.0	0.0	0.0
PTP	**-2.8**	**-2.3**	**-5.0**	**-3.2**	**-3.4**	**-6.6**	**-3.3**	**-2.6**	**-5.9**	**-6.6**	**-8.6**	**-7.9**
Taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net earnings	**-2.8**	**-2.3**	**-5.0**	**-3.2**	**-3.4**	**-6.6**	**-3.3**	**-2.6**	**-5.9**	**-6.6**	**-8.6**	**-7.9**
Net earnings	**-2.8**	**-2.3**	**-5.0**	**-3.2**	**-3.4**	**-6.6**	**-3.3**	**-2.6**	**-5.9**	**-6.6**	**-8.6**	**-7.9**
EPS (adj.)	**-0.14**	**-0.11**	**-0.25**	**-0.13**	**-0.14**	**-0.27**	**-0.08**	**-0.07**	**-0.15**	**-0.17**	**-0.22**	**-0.20**
EPS (rep.)	**-0.14**	**-0.11**	**-0.25**	**-0.13**	**-0.14**	**-0.27**	**-0.08**	**-0.07**	**-0.15**	**-0.17**	**-0.22**	**-0.20**

Source: Inderes

Full-year earnings per share are calculated using the number of shares at year-end.

Balance sheet

Assets	2024	2025	2026e	2027e	2028e
Non-current assets	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**
Goodwill	0.0	0.0	0.0	0.0	0.0
Intangible assets	0.0	0.0	0.0	0.0	0.0
Tangible assets	0.0	0.0	0.0	0.0	0.0
Associated companies	0.0	0.0	0.0	0.0	0.0
Other investments	0.0	0.0	0.0	0.0	0.0
Other non-current assets	0.0	0.0	0.0	0.0	0.0
Deferred tax assets	0.0	0.0	0.0	0.0	0.0
Current assets	**2.6**	**2.7**	**8.6**	**2.1**	**0.3**
Inventories	0.0	0.0	0.0	0.0	0.0
Other current assets	0.0	0.0	0.0	0.0	0.0
Receivables	0.4	0.1	0.3	0.3	0.3
Cash and equivalents	2.1	2.6	8.4	1.8	0.0
Balance sheet total	**2.6**	**2.7**	**8.6**	**2.1**	**0.3**

Source: Inderes

Liabilities & equity	2024	2025	2026e	2027e	2028e
Equity	**-0.3**	**-1.7**	**8.6**	**2.1**	**-6.6**
Share capital	0.1	0.1	0.1	0.1	0.1
Retained earnings	-80.1	-86.7	-92.6	-99.1	-107.8
Hybrid bonds	0.0	0.0	0.0	0.0	0.0
Revaluation reserve	0.0	0.0	0.0	0.0	0.0
Other equity	79.7	84.9	101	101	101
Minorities	0.0	0.0	0.0	0.0	0.0
Non-current liabilities	**2.2**	**3.4**	**0.0**	**0.0**	**5.5**
Deferred tax liabilities	0.0	0.0	0.0	0.0	0.0
Provisions	0.0	0.0	0.0	0.0	0.0
Interest bearing debt	0.0	0.0	0.0	0.0	5.5
Convertibles	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	2.2	3.4	0.0	0.0	0.0
Current liabilities	**0.6**	**0.9**	**0.0**	**0.0**	**1.4**
Interest bearing debt	0.0	0.0	0.0	0.0	1.4
Payables	0.6	0.9	0.0	0.0	0.0
Other current liabilities	0.0	0.0	0.0	0.0	0.0
Balance sheet total	**2.5**	**2.7**	**8.6**	**2.1**	**0.3**


DCF calculation

DCF model	2025	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	2038e	2039e	2040e	TERM
Revenue growth-%	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	NA	497.8 %	155.8 %	52.5 %	14.0 %	4.0 %	-46.6 %	0.0 %
EBIT-%	-63990.0 %	-56630.0 %	-65701.6 %	-86391.7 %	-79420.6 %	-91113.2 %	-108728.5 %	-112275.8 %	-101765.1 %	-64.9 %	71.8 %	88.7 %	92.4 %	93.2 %	93.3 %	93.7 %	0.0 %
EBIT (operating profit)	**-6.4**	**-5.7**	**-6.6**	**-8.6**	**-7.9**	**-9.1**	**-10.9**	**-11.2**	**-10.2**	**-3.0**	**20.1**	**63.7**	**101**	**116**	**121**	**64.9**	
+ Depreciation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Paid taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-11.5	-18.2	-20.9	-21.8	-11.7	
- Tax, financial expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
+ Tax, financial income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Change in working capital	0.6	-1.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Operating cash flow	**-5.8**	**-6.7**	**-6.6**	**-8.6**	**-7.9**	**-9.1**	**-10.9**	**-11.0**	**-10.2**	**-3.0**	**20.1**	**52.2**	**82.9**	**95.3**	**99.3**	**53.2**	
+ Change in other long-term liabilities	1.3	-3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Gross CAPEX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free operating cash flow	**-4.5**	**-10.2**	**-6.6**	**-8.6**	**-7.9**	**-9.1**	**-10.9**	**-11.0**	**-10.2**	**-3.0**	**20.1**	**52.2**	**82.9**	**95.3**	**99.3**	**53.2**	
+/- Other	5.0	14.2	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
FCFF	0.5	4.0	-1.6	-8.6	-7.9	-9.1	-10.9	-11.0	-10.2	-3.0	20.1	52.2	82.9	95.3	99.3	53.2	0.0
Discounted FCFF		**4.0**	**-1.4**	**-6.8**	**-5.6**	**-5.7**	**-6.1**	**-5.5**	**-4.6**	**-1.2**	**7.2**	**16.7**	**23.6**	**24.3**	**22.6**	**10.8**	**0.0**
Sum of FCFF present value		72.2	68.2	69.6	76.4	82.0	87.7	93.8	99.3	104	105	97.9	81.2	57.6	33.4	10.8	0.0

Enterprise value DCF	**72.2**
- Interest bearing debt	0.0
+ Cash and cash equivalents	2.6
+ Associated companies	0.0
-Minorities	0.0
-Dividend/capital return	0.0
Equity value DCF	**74.7**
Equity value DCF per share	**1.9**

WACC	
Tax-% (WACC)	20.0 %
Target debt ratio (D/(D+E)	0.0 %
Cost of debt	8.0 %
Equity Beta	1.68
Market risk premium	4.75%
Liquidity premium	1.00%
Risk free interest rate	3.0 %
Cost of equity	**12.0 %**
Weighted average cost of capital (WACC)	**12.0 %**

Source: Inderes



Summary

Income statement	2023	2024	2025	2026e	2027e
Revenue	0.0	0.0	0.0	**0.0**	**0.0**
EBITDA	0.2	-5.0	-6.4	**-5.7**	**-6.6**
EBIT	0.2	-5.0	-6.4	**-5.7**	**-6.6**
PTP	0.3	-5.0	-6.6	**-5.9**	**-6.6**
Net Income	0.3	-5.0	-6.6	**-5.9**	**-6.6**
Extraordinary items	0.0	0.0	0.0	**0.0**	**0.0**

Balance sheet	2023	2024	2025	2026e	2027e
Balance sheet total	6.7	2.6	2.7	**8.6**	**2.1**
Equity capital	4.7	-0.3	-1.7	**8.6**	**2.1**
Goodwill	0.0	0.0	0.0	**0.0**	**0.0**
Net debt	-6.4	-2.1	-2.6	**-8.4**	**-1.8**

Cash flow	2023	2024	2025	2026e	2027e
EBITDA	0.2	-5.0	-6.4	**-5.7**	**-6.6**
Change in working capital	0.2	-1.5	0.6	**-1.1**	**0.0**
Operating cash flow	0.4	-6.6	-5.8	**-6.7**	**-6.6**
CAPEX	0.0	0.0	0.0	**0.0**	**0.0**
Free cash flow	0.4	-4.4	0.5	**4.0**	**-1.6**

Per share data	2023	2024	2025	2026e	2027e
EPS (reported)	0.01	-0.25	-0.27	**-0.15**	**-0.17**
EPS (adj.)	0.01	-0.25	-0.27	**-0.15**	**-0.17**
OCF / share	0.02	-0.33	-0.24	**-0.17**	**-0.17**
OFCF / share	0.02	-0.22	0.02	**0.10**	**-0.04**
Book value / share	0.23	-0.01	-0.07	**0.22**	**0.05**
Dividend / share	0.00	0.00	0.00	**0.00**	**0.00**

Source: Inderes

The market cap and enterprise value in the table consider the expected change in the number of shares and net debt for the forecast years. Per-share figures are calculated using the number of shares at year-end.

Disclaimer and recommendation history

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy	The 12-month risk-adjusted expected shareholder return of the share is very attractive
Accumulate	The 12-month risk-adjusted expected shareholder return of the share is attractive
Reduce	The 12-month risk-adjusted expected shareholder return of the share is weak
Sell	The 12-month risk-adjusted expected shareholder return of the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return is Inderes' view of the risk taken by the investor, which varies considerably between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.

Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at www.inderes.fi/research-disclaimer.

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

Recommendation history (>12 mo)

Date	Recommendation	Target	Share price
6/19/2024	Accumulate	2.20 €	1.63 €
8/23/2024	Accumulate	2.20 €	1.60 €
3/7/2025	Accumulate	1.90 €	1.33 €
8/22/2025	Accumulate	2.10 €	1.79 €
10/9/2025	Reduce	2.50 €	2.78 €
11/20/2025	Accumulate	2.50 €	2.00 €
12/22/2025	Accumulate	2.50 €	1.98 €
1/9/2026	Reduce	2.50 €	2.55 €
3/6/2026	Accumulate	2.40 €	2.03 €
6/3/2026	Reduce	2.20 €	2.27 €
8/21/2026	Accumulate	2.00 €	1.53 €
11/26/2026	Buy	1.90 €	1.32 €



CONNECTING INVESTORS AND COMPANIES.

Inderes democratizes financial information by connecting investors and listed companies. For investors, we are an investing community and a trusted source of financial information and equity research. For listed companies, we are a partner in delivering high-quality investor relations. Over 500 listed companies in Europe use our investor relations products and equity research services to provide better investor communications to their shareholders.

Our goal is to be the most investor-minded company in finance. Inderes was founded in 2009 by investors, for investors. As a Nasdaq First North-listed company, we understand the day-to-day reality of our customers.

Inderes Ab
Vattugatan 17, 5tr
Stockholm
+46 8 411 43 80

inderes.se

Inderes Oyj
Porkkalankatu 5
00180 Helsinki
+358 10 219 4690

inderes.fi

inderes.